BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI evidence brief
What we can confirm
- BioSniper Score:
- 9.3 / 10
- Lead Asset:
- belbuca (Approved)
What it means
What to watch
Prepared research question
What matters most for BDSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 5 pipeline candidates · 2 FDA decisions for BIODELIVERY SCIENCES INTERNATIONAL INC.
Run BIODELIVERY SCIENCES INTERNATIONAL INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIODELIVERY SCIENCES INTERNATIONAL INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is BIODELIVERY SCIENCES INTERNATIONAL INC's lead drug candidate?
BIODELIVERY SCIENCES INTERNATIONAL INC's most advanced tracked candidate is belbuca (Approved) for Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Who is the CEO of BIODELIVERY SCIENCES INTERNATIONAL INC?
Jeffrey Bailey is the chief executive officer of BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI).
What therapeutic areas does BIODELIVERY SCIENCES INTERNATIONAL INC focus on?
BIODELIVERY SCIENCES INTERNATIONAL INC develops therapies across Oncology, Neurology, Pain, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.